Botulinum toxin treatment of urethral and bladder dysfunction

Acta Medica Okayama

Volumn 56, Issue 6, 2002, Pages 271-277

  Yokoyama, Teruhiko ^a   Kumon, Hiromi ^a   Smith, Christopher P ^b   Somogyi, George T ^b   Chancellor, Michael B ^b  

^a OKAYAMA UNIVERSITY   (Japan)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Bladder; Botulinum toxin; Urethra

Indexed keywords

BOTULINUM TOXIN; ISOPROTEIN;

BLADDER DISEASE; DRUG EFFECT; HUMAN; REVIEW; SENSORY NERVE CELL; URETHRA DISEASE;

BOTULINUM TOXINS; HUMANS; NEURONS, AFFERENT; PROTEIN ISOFORMS; URETHRAL DISEASES; URINARY BLADDER DISEASES;

EID: 0038005335     PISSN: 0386300X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. van Ermengem E: Ueber einen neuen anaeroben Bacillus and seine Beziehungen zum Botulisms. Ztsch Hyg Infekt (1897) 26, 1-56.
2. Petit H, Wiart L, Gaujard E, Le Breton F, Ferriere JM, Lagueny A, Joseph PA and Barat M: Botulinum A toxin treatment for detrusor-sphincter dyssynergia in spinal cord disease. Spinal Cord (1998) 36, 91-94.
3. Dykstra DD, Sidi AA, Scott AB, Pagel JM and Goldish GD: Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol (1988) 139, 919-922.
4. Dykstra DD and Sidi A: Treatment of detrusor-sphincter dyssyngeria with botulinum A toxin: A double blind study. Arch Phys Med Rehabil (1990) 71, 24-26.
5. Schurch B, Stohrer M, Kramer G, Schmid DM, Gaul G and Hauri D: Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: A new alternative to anticholinergic drugs? Preliminary results. J Urol (2000) 164, 692-697.
6. Dickson EC: Botulism. A clinical and experimental study. Rockefeller Inst Med Res Mong (1918) 8, 1-25.
7. Dolly JO: General properties and cellular mechanisms of neurotoxins; in Therapy with Botulinum Toxin, Jankovic J and Hallet M eds, Marcel Dekker, New York (1994) pp 153-268.
8. Simpson LL: Peripheral actions of the botulinum toxins, in Botulinum Neurotoxin and Tetanus Toxin, Simpson LL ed, Academic Press, New York (1989) pp 153-178.
9. Barinaga M: Secrets of secretion revealed. Science (1993) 260, 487-489.
10. Schiavo G, Santucci A, Dasgupta BR, Mehta PP, Jontes J, Benfenati F, Wilson MC and Montecucco C: Botulinum neurotoxins serotypes A and E cleave SNAP-25 at distinct COOH-terminal peptide bonds. FEBS Lett (1993) 335, 99-103.
11. Grazko MA, Polo KB and Jabbari B: Botulinum toxin A for spasticity, muscle spasms, and rigidity. Neurology (1995) 45, 712-717.
12. Jankovic J, Schwartz K and Donovan DT: Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm J Neurol Neurosurg Psychiatry (1990) 53, 633-639.
13. Scott AB: Botulinum toxin injection of eye muscles to correct strabismus. Trans Am Ophthalmol Soc (1981) 79, 734-770.
14. Kolbasnik J, Waterfall WE, Fachnie B, Chen Y and Tougas G: Long-term efficacy of Botulinum toxin in classical achalasia: A prospective study. Am J Gastroent (1999) 94, 3434-3439.
15. Schnider P, Binder M, Kittler H, Birner P, Starkel D, Wolff K and Auff E: A randomized, double-blind, placebo-controlled trial of botulinum A toxin for severe axillary hyperhidrosis. Br J Dermatol (1999) 140, 677-680.
16. Lapides J, Diokno AC, Silber SJ and Lowe BS: Clean, intermittent self-catheterization in the treatment of urinary tract disease. Trans Am Assoc Genitourin Surg (1971) 63, 92-96.
17. Koyanagi T, Morita H, Takamatsu T, Taniguchi K and Shinno Y: Radical transurethral resection of the prostate in male paraplegics revisited: Further clinical experience and urodynamic considerations for its effectiveness. J Urol (1987) 137, 72-76.
18. Borodic GE, Joseph M, Fay L, Cozzolino D and Ferrante RJ: Botulinum A toxin for the treatmnent of spasmodic torticollis: Dysphagia and regional toxin spread. Head Neck (1990) 12, 392-399.
19. de Paiva A, Meunier FA, Molgo J, Aoki KR and Dolly JO: Functional repair of motor endplates after botulinum neurotoxin type A poisoning: Biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci (1999) 96, 3200-3205.
20. Phelan MW, Franks M, Somogyi GT, Yokoyama T, Fraser MO, Lavelle JP, Yoshimura N and Chancellor MB: Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction. J Urol (2001) 165, 1107-1110.
21. Schurch B, Hauri D, Rodic B, Curt A, Meyer M and Rossier AB: Botulinum-A toxin as a treatment of detrusor-sphincter dyssyngeria: A prospective study in 24 spinal cord injury patients. J Urol (1996) 155, 1023-1029.
22. McNeil BK, Smith CP, Franks ME, Ghosh R, de Groat WC, Chancellor MB and Somogyi GT: Effect of botulinum toxin A on urethral neurotransmitter release: Implications on somatic/autonomic nerve transmission [Abstract]. J Urol (2001) 165, 277.
23. Smith CP, O'Leary M, Erickson J, Somogyi GT and Chancellor MB: Botulinum toxin urethral sphincter injection resolves urinary retention after pubovaginal sling operation. Int Urogynecol J Pelvic Floor Dysfunct (2002) 13, 185-186.
24. Schurch B, Stohrer M, Kramer G, Grosse J, Schmid D and Hauri D: Botulinum Toxin-A to treat detrusor hyperreflexia in spinal cord injured patients. Neurourol Urodyn (2001) 20, 521-522.
25. Del Popolo G: Botulinum-A toxin in the treatment of detrusor hyperreflexia Neurourol Urodyn (2001) 20, 522-524.
26. Radziszewski P, Dobronski P and Borkowski A: Treatment of the non-neurogenic storage and voiding disorders with the chemical denervation caused by botulinum toxin type A- A pilot study. Neurourol Urodyn (2001) 20, 410-412.
27. Zermann DH, Ishigooka M, Schubert J and Schmidt RA: Trigonum and bladder base injection of botulinum toxin A (BTX) in patients with severe urgency-frequency-syndrome refractory to conservative medical treatment and electrical stimulation. Neurourol Urodyn (2001) 20, 412-413.
28. Chancellor MB and Smith CP: One surgeon's experience in 50 patients with botulinum toxin injection into the bladder and urethra [Abstract]. J Urol (2002) 167, 249.
29. Carpenter FG: Motor responses of the urinary bladder and skeletal muscle in botulinum intoxicated rates. J Physiol (1967) 188, 1-11.
30. Bigalke H and Habermann E: Blockade by tetanus and botulinum A toxin of postganglionic cholinergic nerve endings in the myenteric plexus. Naunyn Schmiedebergs Arch Pharmacol (1980) 312, 255-263.
31. Mackenzie I, Burnstock G and Dolly JO: The effects of purified botulinum neurotoxin type A on cholinergic, adrenergic and non-adrenergic, atropine-resistant autonomic neuromuscular transmission. Neuroscience (1982) 7, 997-1006.
32. Franks ME, Somogyi GT, Phelan MW, Fraser MO, Yokoyama T, Ghosh R, de Groat WC and Chancellor MB: Botulinum toxin injection into the bladder wall decreases acetylcholine (ACh) and norepinephrine (NE) release: Potential treatment for the overactive bladder [Abstract]. J Urol (2000) 163, 42.
33. Aoki KR: Pharmacology and immunology of botulinum toxin serotypes. J Neurol (2001) 248 (Supple I), 3-10.
34. th Annual Conference, 2001.
35. Welch MJ, Purkiss JR and Foster KA: Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon (2000) 38, 245-258.
36. Purkiss JR, Welch MJ, Doward S, Foster KA and Quinn CP: A method for the measurement of [3H]-glutamate release from cultured dorsal root ganglion neurons. Biochem Soc Trans (1998) 26, S108.
37. Cui M and Aoki KR: Botulinum toxin type A (BTX-A) reduces inflammatory pain in the rat formalin model. Cephalagia (2000) 20, 414.
38. Smith CP, Fraser MO, Bartho L, de Groat WC, Chancellor MB and Somogyi GT: Botulinum toxin A inhibits afferent nerve evoked bladder strip contractions [Abstract]. J Urol (2002) 167, 41.
39. Smith CP, Somogyi GT and Chancellor MB: Botulinum toxin: Poisoning the spastic bladder and urethra. Rev Urol (2002) 4, 61-68.